Sylvant

(siltuximab)
Sylvant 100 MG InjectionSylvant 400 MG Injection
NO BOXED WARNING

Dosage & administration

For intravenous infusion only.

Administer as an 11 mg/kg dose given over 1 hour by intravenous infusion every 3 weeks.

drug label

Sylvant prescribing information

prior authorization

Sylvant prior authorization resources

Most recent Sylvant prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Short Acting Opioid Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Western NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Feb 27, 2024Arizona - Uniform Prior Authorization Form
Verified: Feb 27, 2024Colorado - Uniform Prior Authorization Form
Verified: Feb 27, 2024Hawaii - Uniform Prior Authorization Form
Verified: Feb 27, 2024Illinois - Uniform Prior Authorization Form
Verified: Feb 27, 2024Indiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Louisiana - Uniform Prior Authorization Form
Verified: Feb 27, 2024Michigan - Uniform Prior Authorization Form
Verified: Feb 27, 2024Minnesota - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Feb 27, 2024New Mexico - Uniform Prior Authorization Form
Verified: Feb 27, 2024Oregon - Uniform Prior Authorization Form
Verified: Feb 27, 2024Texas - Uniform Prior Authorization Form
Learn More

Benefits investigation

EUSA Patient Connect Program Form
Learn More

financial assistance

Sylvant financial assistance options

Co-pay savings program

commercial only
EUSA Patient Connect Program Form
Enroll in Patient Savings Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
EUSA Patient Connect Program Form
EUSA Patient Connect Patient Assistance Program
Learn More

PubMed™ | Sylvant

Sylvant PubMed™ News

patient education

Sylvant patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

Patient Liaison Program
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Sylvant
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Sylvant Infusion
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Sylvant FAQs

What is the risk of using SYLVANT during pregnancy?The limited available information on SYLVANT use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage. However, infants born to pregnant women treated with SYLVANT may be at increased risk of infection. It is advised to inform pregnant women of the potential risk to a fetus.
What is the estimated background risk of birth defects and miscarriage in the general population?In the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.
What are the fetal/neonatal adverse reactions of SYLVANT?Monoclonal antibodies like SYLVANT are transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Infants born to pregnant women treated with SYLVANT may be at increased risk of infection. It is advised to consider the risks and benefits of administering live or live-attenuated vaccines to infants exposed to SYLVANT in utero.
Is it safe to use SYLVANT during lactation?There are no data on the presence of siltuximab in human milk, the effects on the breastfed child, or the effects on milk production. However, low levels of the human antibody to IL-6 were present in the milk of lactating cynomolgus monkeys. Because of the potential for serious adverse reactions in the breastfed child including gastrointestinal perforations, it is advised to not breastfeed during treatment with SYLVANT and for 3 months after the last dose.
What is the recommended contraception for female patients of reproductive potential using SYLVANT?SYLVANT may cause embryo-fetal harm when administered to pregnant women. Female patients of reproductive potential should use effective contraception during treatment with SYLVANT and for 3 months after the last dose.
Is SYLVANT safe to use in pediatric patients?The safety and efficacy of SYLVANT have not been established in pediatric patients.
Is there a difference in safety profile between elderly and younger patients using SYLVANT?No overall differences in safety profile were observed between elderly patients and younger patients in clinical studies. However, clinical studies did not include sufficient numbers of patients aged 65 years and older to determine the effect of age on efficacy in MCD population.
FAQ Data Source